Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

PURPOSE: Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM). In preclinical studies, lenalidomide sensitized MM cells to bortezomib and dexamethasone. This phase I, dose-escalation study (ie, NCT00153933) evaluated safety and determined the maximum-toler...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Richardson, Paul G., Weller, Edie, Jagannath, Sundar, Avigan, David E., Alsina, Melissa, Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Ghobrial, Irene M., Doss, Deborah, Warren, Diane L., Lunde, Laura E., McKenney, Mary, Delaney, Carol, Mitsiades, Constantine S., Hideshima, Teru, Dalton, William, Knight, Robert, Esseltine, Dixie-Lee, Anderson, Kenneth C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2799050/
https://ncbi.nlm.nih.gov/pubmed/19786667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.2679
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados